Company · INCY
Incyte
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
6 still marketed
Novel approvals
5
Approvals since 2021
13
Originals and new uses
Phase 3 trials
62
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zynyz new use OrphanMay 18, 2026
- Jakafi Xr approved OrphanMay 1, 2026
- Zynyz new use OrphanMar 30, 2026
- Zynyz new use OrphanDec 17, 2025
- Opzelura new use Sep 18, 2025
- Zynyz new use Priority reviewOrphanMay 15, 2025
- Niktimvo approved NovelPriority reviewOrphanAug 14, 2024
- Zynyz approved NovelAccelerated approvalPriority reviewOrphanMar 22, 2023
- Jakafi new use Priority reviewOrphanDec 19, 2022
- Pemazyre new use Breakthrough therapyPriority reviewOrphanAug 26, 2022
Drugs in development (11)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- INCB123667Phase 33 trials
Incyte · Ovarian Cancer
- INCA33890Phase 32 trials
Incyte · CRC (Colorectal Cancer)
- INCA033989Phase 31 trial
Incyte · Essential Thrombocythemia
- INCB161734Phase 31 trial
Incyte · Solid Tumors
- INCAGN02385Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- INCAGN02390Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- itacitinibINCB039110Phase 22 trials
Incyte · B-Cell Malignancies, Lung Cancer
- parsaclisibINCB050465Phase 22 trials
Incyte · Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma, B-Cell Malignancies
- epacadostatPhase 21 trial
Incyte · Endometrial Cancer
- INCA000585Phase 21 trial
Incyte · Immune Thrombocytopenia
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07284849 · 700 participants (planned) · Start Mar 5, 2026 · Primary completion Dec 29, 2028
Drug: INCA33890; Placebo and 2 more · For: CRC (Colorectal Cancer)
Sites: Mobile, Alabama; Tucson, Arizona; Fountain Valley, California · 297 sites in all
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06855498 · 600 participants (planned) · Start Feb 28, 2025 · Primary completion Feb 28, 2028
Drug: povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 305 sites in all
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07522073 · 588 participants (planned) · Start Apr 9, 2026 · Primary completion Sep 15, 2028
Drug: INCB161734; Placebo and 1 more · For: Solid Tumors
Sites: Birmingham, Alabama; Anchorage, Alaska; Chandler, Arizona · 230 sites in all
Incyte CorporationIncyte (INCY)
NCT06615050 · 572 participants (planned) · Start Apr 2, 2025 · Primary completion Jan 17, 2031
Drug: Tacrolimus (Tac); Methotrexate (MTX) and 3 more · For: Graft-versus-host Disease (GVHD)
Sites: Palo Alto, California; San Francisco, California; Miami, Florida · 30 sites in all
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07623200 · 426 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 15, 2029
Drug: INCA033989; Best Available Treatment · For: Essential Thrombocythemia
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 196 sites in all
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06804811 · 250 participants (planned) · Start Nov 13, 2025 · Primary completion Apr 30, 2027
Drug: Ruxolitinib Cream; Vehicle Cream · For: NonSegmental Vitiligo
Sites: Buenos Aires, Argentina; Derqui-pilar, Argentina; Mar del Plata, Argentina · 78 sites in all
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06585774 · 240 participants (planned) · Start Jan 21, 2025 · Primary completion Sep 28, 2027
Drug: INCA034176; Placebo and 1 more · For: Chronic Graft-versus-host-disease
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 133 sites in all
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06548360 · 180 participants (planned) · Start Jan 24, 2025 · Primary completion Jun 5, 2028
Drug: Ruxolitinib Cream; Vehicle Cream · For: NonSegmental Vitiligo
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 98 sites in all
Marketed drugs (6)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.